Compugen Ltd. (CGEN) is a clinical-stage immuno-oncology company headquartered in Holon, Israel, listed on the Nasdaq and the Tel Aviv Stock Exchange. Its shares carry a "Strong Buy" consensus among the analysts tracked, but coverage is thin and targets are tightly grouped.
Five verifiable targets were reviewed: H.C. Wainwright at $4.00 (reiterated October 12, 2026), Stifel at $4.00, Lake Street at $6.00 (initiated April 7, 2026), Leerink Partners at $5.00 (lowered from $13.00 on May 21, 2026), and a further $4.00 target. This produces an approximate range of $4.00 to $6.00 and an average analyst price target of $4.60. The figure is a calculation of the individual targets, not an official published consensus; some data providers round the average to $5.00.
All five analysts sit on the constructive side, but the narrow spread reflects a shared view that Compugen's value is anchored to discrete clinical events rather than near-term fundamentals. Leerink's sharp cut from $13 to $5 in mid-2026 illustrates how quickly expectations can recalibrate for a pre-revenue biotech.
The stock closed near $2.13 after reporting third-quarter 2026 results, having traded as low as roughly $1.87 days earlier and near $2.94 in late August. Moving to $4.60 would require about 116% upside — a very large move that would depend on re-rating the shares around data catalysts rather than earnings growth.
For the third quarter, Compugen reported a net loss of $0.06 per share, beating a roughly $0.08 estimate, on revenue of about $3.8 million versus roughly $1.9 million a year earlier. The company held approximately $117.5 million in cash and investments as of September 30, 2026, with management guiding to a runway into 2029. The path to $4.60, however, runs primarily through a binary clinical readout expected by the end of the first quarter of 2027.
The central catalyst is COM701, a potential first-in-class anti-PVRIG antibody being evaluated in the fully enrolled MAIA-Ovarian trial (62 patients randomized 2:1 against placebo). A credible efficacy signal could transform how investors value the wholly owned asset.
Partner programs provide additional optionality. Rilvegostomig, a PD-1/TIGIT bispecific antibody, is being advanced by AstraZeneca (AZN) across 12 Phase 3 trials, with high-level results from ARTEMIDE-Biliary01 now expected in the second half of 2027. Compugen is eligible for up to $195 million in milestones plus mid-single-digit royalties. Separately, Gilead (GILD) is advancing GS-0321, an anti-IL-18 binding protein antibody, under a deal worth up to $758 million in additional milestones plus royalties. A strengthened cash runway into 2029 reduces near-term financing risk.
The MAIA-Ovarian study is exploratory and not powered for statistical significance, so even a favorable readout may not establish an approval-ready package. Management's framing of success has shifted toward the "totality of the data," which leaves room for an ambiguous result.
Third-quarter revenue consisted largely of recognizing portions of Gilead's upfront and IND milestone payments — non-cash accounting recognition rather than new demand. A significant share of Compugen's potential value depends on partner execution, and the next AstraZeneca milestone is tied to BLA (Biologics License Application) acceptance, meaning a positive trial alone would not trigger payment. Emerging antibody-drug conjugate competition in ovarian maintenance adds further uncertainty.
After the August report, shares rallied toward roughly $2.94 before giving back the entire move. The stock has traded near a recent low around $1.87 and, entering November, sat roughly 14% below its $2.29 200-day moving average. A sustained move above that average and the low-$3.00 area would be a notable structural shift, while the $4.00–$6.00 target band sits well above any recent resistance zone, underscoring how much the thesis depends on clinical data rather than technical repair.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms may differ and no specific horizon was stated for all five. Investors should watch the MAIA-Ovarian data expected by the end of the first quarter of 2027, the rilvegostomig Phase 3 readout anticipated in the second half of 2027, any GS-0321 data disclosures (which require Gilead's cooperation), cash burn, and any analyst target revisions around these events.
AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a binary, catalyst-heavy name like Compugen, such tools can help traders track shifts in momentum and sentiment without manually screening charts. Traders can use the signals to discover opportunities, monitor existing positions, and spot changing trends more efficiently. Consider exploring these signals as one input within a broader research process.
Whether CGEN can reach $4.60 hinges less on quarterly results and more on whether COM701 delivers a credible signal in the MAIA-Ovarian readout and whether partnered programs keep advancing. The target — the average of five analyst price targets in a $4.00 to $6.00 range — implies roughly 116% upside from recent levels, a very large move that assumes the market begins pricing pipeline success well before regulatory approval. Strong cash runway and milestone-rich partnerships support the case, while a small, unpowered trial, partner-dependent value, and largely non-cash revenue are the principal obstacles. The MAIA-Ovarian data, expected by the end of the first quarter of 2027, is the clearest single determinant of the debate.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with RXRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To CGEN | 1D Price Change % | ||
|---|---|---|---|---|
| CGEN | 100% | N/A | ||
| RXRX - CGEN | 39% Loosely correlated | +1.13% | ||
| RCUS - CGEN | 37% Loosely correlated | +0.70% | ||
| ABCL - CGEN | 37% Loosely correlated | -4.09% | ||
| AXON - CGEN | 36% Loosely correlated | +4.26% | ||
| GHRS - CGEN | 36% Loosely correlated | -1.58% | ||
More | ||||